权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

MUSC Digestive Disease Research Core Center

MUSC消化疾病研究核心中心

基本信息

批准号：
10608960
负责人：
DON C. ROCKEY
金额：
$ 108.76万
依托单位：
MEDICAL UNIVERSITY OF SOUTH CAROLINA
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-04-15 至 2025-03-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10608960
关键词：
Acceleration Area Award Basic Science Biology Biomedical Research Cell model Cells Clinical Clinical Research Clinical Sciences Collaborations Colon Complement Core Facility Curiosities Dedications Development Digestive System Disorders Disease Ensure Esophagitis Esophagus Evaluation Fibrosis Fostering Foundations Functional disorder Funding Gastrointestinal Diseases Gastrointestinal tract structure Goals Health Healthcare Hepatocyte Image Imaging Techniques Inflammation Inflammatory Bowel Diseases Injury Institution Investigation Investments Leadership Liver Liver diseases Malignant Neoplasms Medical Mentorship Mission Modeling National Institute of Diabetes and Digestive and Kidney Diseases Organ Pancreas Participant Pathogenesis Patient-Focused Outcomes Patients Performance Proteomics Research Research Infrastructure Research Personnel Resources Scholarship Science Scientific Inquiry Small Intestines South Carolina Stomach Structure Technology Tissues Translating Translational Research Universities Vision Work base career development cell injury chronic pancreatitis design driving force flexibility gastrointestinal human disease human model imaging capabilities improved innovation instrumentation liver injury mass spectrometric imaging member novel novel therapeutics organ injury process improvement programs research study success tissue culture

项目摘要

Center Overview - Abstract The vision for the Medical University of South Carolina (MUSC) Digestive Disease Research Core Center (DDRCC) is to create a culture of curiosity, scholarship, and investigation around our central theme. Our theme is informed by the pathogenesis of disease in the gastrointestinal tract, from cellular injury, inflammation, fibrosis, and ultimately end organ dysfunction and disease. Our specific emphasis on human disease is part of our rationale for the extension of the continuum of our theme - from injury to disease. Further, we expect the work by Center members to lead to new treatments for patients with gastrointestinal disease. Our specific aims are integrated with the specific goal to serve our Research Base/Full Members and our mission; specific aims are as follows: (1) First, we will foster collaboration among digestive and liver disease researchers. We will leverage collaborations among MUSC investigators to further augment our research capacity while ensuring the success of a critical mass of outstanding researchers in digestive and liver diseases. This will be supported through multiple synergistic efforts as described in the Administrative Core including DDRCC leadership and Enrichment and Pilot and Feasibility Programs. (2) We will develop sustainable scientific core resources that will specifically support digestive and liver disease studies while leveraging institutional investments. The DDRCC scientific cores include: a) Analytical Cell Models Core, which will deliver high quality, pure primary liver cells and produce state-of-the-art tissue culture models; b) Advanced Imaging Core with advanced cell- and tissue-based imaging techniques and instrumentation; and c) Proteomics Core with innovative mass spectrometry imaging capabilities. These cores are complemented by a committed Clinical Component which provides support for the design, implementation and analysis of research studies to improve clinical outcomes for patients with digestive diseases. Finally, we will (3) Promote the long- term success and sustainability of the DDRCC through dedicated mentorship of New Investigators, a rigorous Center evaluation and process improvement strategy, mission alignment with other centers at MUSC, and specific long-term institutional commitments to the Center. The MUSC DDRCC is made up of 29 Full Members focused specifically on our theme, and who constitute our Research Base of $10.8M. We also have 31 Associate Members who are active participants in the Center. The DDRCC has enormous potential to answer important questions, open new areas for further inquiry, and result in potential new therapeutic discoveries that will be translated to new treatments for patients with digestive and liver disease.

中心概述-摘要南卡罗来纳州医科大学消化疾病研究核心中心的愿景（DDRCC）是围绕我们的中心主题创造一种好奇心，学术和调查的文化。我们的主题通过胃肠道疾病的发病机制，从细胞损伤，炎症，纤维化，最终导致器官功能障碍和疾病。我们对人类疾病的特别重视是我们的一部分，我们的主题的连续性的延伸的理由-从伤害到疾病。此外，我们希望这项工作由中心成员，导致新的治疗胃肠疾病的患者。我们的具体目标与服务于我们的研究基地/正式成员和我们的使命的具体目标相结合; 具体目标如下：（1）首先，我们将促进消化系统和肝脏疾病之间的合作研究人员我们将利用MUSC调查人员之间的合作，进一步扩大我们的研究这将提高我们的能力，同时确保消化和肝脏疾病领域的大量杰出研究人员取得成功。这将通过行政核心中所述的多项协同努力得到支持，复员方案协调中心领导能力、充实方案、试点方案和可行性方案。(2)我们将持续发展科学核心资源，将专门支持消化和肝脏疾病研究，利用机构投资。DDRCC科学核心包括：a）分析细胞模型核心，其将递送高质量、纯的原代肝细胞并产生最先进的组织培养模型; B）先进的成像核心与先进的细胞和组织为基础的成像技术和仪器;和c） Proteomics Core具有创新的质谱成像功能。这些核心由一个承诺的临床组件，为研究的设计、实施和分析提供支持研究，以改善消化系统疾病患者的临床结果。最后，我们将（3）促进长期- 通过新调查员的专门指导，中心评估和流程改进策略，与MUSC其他中心的使命一致性，以及对该中心的具体长期机构承诺。 MUSC DDRCC由29名正式成员组成，他们专门关注我们的主题，研究经费1080万元。我们还有31个准成员，他们是中心的积极参与者。的 DDRCC具有回答重要问题的巨大潜力，为进一步调查开辟了新的领域，并导致潜在的新的治疗发现，将转化为新的治疗方法，为患者的消化和肝脏疾病

项目成果

期刊论文数量（129）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

The Emerging Epidemic of Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: True, True, and Related?

新出现的非酒精性脂肪肝与心血管风险的流行：真实、真实和相关吗？

DOI：
10.1007/s10620-020-06113-9
发表时间：
2020
期刊：
Digestive diseases and sciences
影响因子：
3.1
作者：
Morningstar,JordanE;Syn,Wing-Kin;Litwin,SheldonE
通讯作者：
Litwin,SheldonE

Insurance type impacts bronchoscopy for foreign body aspiration: An analysis of the Kids' Inpatient Database.

保险类型影响异物抽吸的支气管镜检查：儿童住院数据库的分析。

DOI：
10.1016/j.ijporl.2020.110023
发表时间：
2020
期刊：
International journal of pediatric otorhinolaryngology
影响因子：
1.5
作者：
Patel,Terral;Clemmens,ClariceS;White,DavidR;Ford,MarvellaE;Andrews,AnneL;Pecha,PhayvanhP
通讯作者：
Pecha,PhayvanhP

Impact of a multidisciplinary multimodal opioid minimization initiative in kidney transplant recipients.

多学科多模式阿片类药物最小化倡议对肾移植受者的影响。

DOI：
10.1111/ctr.14006
发表时间：
2020
期刊：
Clinical transplantation
影响因子：
2.1
作者：
Rohan,VinayakS;Taber,DavidJ;Patel,Neha;Perez,Caroline;Pilch,Nicole;Parks,Sara;Bolin,Eric;Nadig,SatishN;Baliga,PrabhakarK;Fleming,JamesN
通讯作者：
Fleming,JamesN

Maintaining Equity and Access: Successful Implementation of a Virtual Kidney Transplantation Evaluation.

维护公平和机会：成功实施虚拟肾移植评估。

DOI：
10.1016/j.jamcollsurg.2020.12.003
发表时间：
2021
期刊：
Journal of the American College of Surgeons
影响因子：
5.2
作者：
Rohan,VinayakS;Pilch,Nicole;Cassidy,Deborah;McGillicuddy,John;White,Jared;Lin,Angello;Nadig,SatishN;Taber,DavidJ;Dubay,Derek;Baliga,PrabhakarK
通讯作者：
Baliga,PrabhakarK

Normal or near normal aminotransferase levels in patients with alcoholic cirrhosis.

酒精性肝硬化患者的转氨酶水平正常或接近正常。